Atovaquone

Active ingredient: Atovaquone

In short: Atovaquone oral suspension is indicated for the prevention of Pneumocystis jiroveciipneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderat

Forms & strengthsAtovaquone oral suspension, USP is a bright yellow, citrus-flavored, oral suspension containing 750 mg of atovaquone, USP in 5 mL. Atovaquone oral suspension, USP is supplied in 210-mL bottles.
LabelAvKARE
Label updatedJun 16, 2026

What is Atovaquone used for?

Atovaquone oral suspension is indicated for the prevention of

Pneumocystis jiroveciipneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX).

Atovaquone oral suspension is indicated for the acute oral treatment of mild-to-moderate PCP in adults and adolescents (aged 13 years and older) who cannot tolerate TMP-SMX.

Clinical experience with atovaquone oral suspension for the treatment of PCP has been limited to subjects with mild-to-moderate PCP (alveolar-arterial oxygen diffusion gradient [(A-a)DO

2] ≤45 mm Hg). Treatment of more severe episodes of PCP with atovaquone oral suspension has not been studied. The efficacy of atovaquone in subjects who are failing therapy with TMP-SMX has also not been studied.

Atovaquone dosage

The recommended oral dosage is 1,500 mg (10 mL) once daily administered with food.

The recommended oral dosage is 750 mg (5 mL) twice daily (total daily dose = 1,500 mg) administered with food for 21 days.

Administer atovaquone oral suspension with food to avoid low plasma atovaquone concentrations that may limit response to therapy

.

Atovaquone Oral Suspension Bottle

Shake bottle gently before administering the recommended dosage.

How to take Atovaquone — instructions & advice from the label

Important Administration Instructions

Advise patients to take the prescribed dose of atovaquone oral suspension as directed.

Advise patients to take their daily doses of atovaquone oral suspension with food, as food will significantly improve the absorption of the drug

.

Advise patients to shake atovaquone oral suspension gently before use each time

.

Severe Cutaneous Adverse Reactions (SCARs)

Advise patients about the signs and symptoms of serious skin manifestations. Instruct patients to stop taking atovaquone oral suspension immediately and promptly report the first signs or symptoms of skin rash, mucosal lesions, or any other sign of hypersensitivity

.

Lactation

Inform women with HIV-1 that the potential risks of breastfeeding include HIV-1 transmission (in infants without HIV-1)

.

Manufactured for:

AvKARE

Pulaski, TN 38478

Mfg. Rev. 04-2026-05

AV 05/26 (M)

Warnings & precautions

Do not take this medicine if: Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions to atovaquone or any of the components of atovaquone oral suspension

.

Absorption of orally administered atovaquone oral suspension is limited but can be significantly increased when the drug is taken with food. Failure to administer atovaquone oral suspension with food may result in lower plasma atovaquone concentrations and may limit response to therapy. Consider therapy with other agents in patients who have difficulty taking atovaquone oral suspension with food or in patients who have gastrointestinal disorders that may limit absorption of oral medications

.

Cases of cholestatic hepatitis, elevated liver enzymes, and fatal liver failure have been reported in patients treated with atovaquone

.

If treating patients with severe hepatic impairment, closely monitor patients following administration of atovaquone.

Cases of severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and erythema multiforme (EM) have been reported in patients treated with atovaquone

.

SCARs can be life-threatening or fatal. If symptoms or signs of SCARs develop, discontinue atovaquone immediately and institute appropriate therapy. Patients who have developed SCARs with the use of atovaquone must not receive atovaquone

.

Atovaquone side effects

The following adverse reactions are discussed in another section of the labeling:

Hepatotoxicity

.

Severe Cutaneous Adverse Reactions

.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Additionally, because many subjects who participated in clinical trials with atovaquone had complications of advanced human immunodeficiency virus (HIV) disease, it was often difficult to distinguish adverse reactions caused by atovaquone from those caused by underlying medical conditions.

PCP Prevention Trials

In 2 clinical trials, atovaquone oral suspension was compared with dapsone or aerosolized pentamidine in HIV-1-infected adolescent (13 to 18 years) and adult subjects at risk of PCP (CD4 count <200 cells/mm

3or a prior episode of PCP) and unable to tolerate TMP-SMX.

Dapsone Comparative Trial:In the dapsone comparative trial (n = 1,057), the majority of subjects were white (64%), male (88%), and receiving prophylaxis for PCP at randomization (73%); the mean age was 38 years. Subjects received atovaquone oral suspension 1,500 mg once daily (n = 536) or dapsone 100 mg once daily (n = 521); median durations of exposure were 6.7 and 6.5 months, respectively. …

Drug interactions

Concomitant administration of rifampin or rifabutin and atovaquone oral suspension is known to reduce atovaquone concentrations

.

Concomitant administration of atovaquone oral suspension and rifampin or rifabutin is not recommended.

Concomitant administration of tetracycline and atovaquone oral suspension has been associated with a reduction in plasma concentrations of atovaquone

.

Caution should be used when prescribing tetracycline concomitantly with atovaquone oral suspension. Monitor patients for potential loss of efficacy of atovaquone if co-administration is necessary.

Metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available

.

Concomitant administration of atovaquone and indinavir did not result in any change in the steady-state AUC and C

maxof indinavir but resulted in a decrease in the C

troughof indinavir

.

Caution should be exercised when prescribing atovaquone oral suspension with indinavir due to the decrease in trough concentrations of indinavir. Monitor patients for potential loss of efficacy of indinavir if co-administration with atovaquone oral suspension is necessary.

About this medicine

Atovaquone is a quinone antimicrobial drug for oral administration. The chemical name of atovaquone is

trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione. Atovaquone, USP is a yellow crystalline solid that is practically insoluble in water. It has a molecular weight of 366.84 and the molecular formula C

22H

19ClO

3. The compound has the following structural formula:

Atovaquone oral suspension, USP is a formulation of micro-fine particles of atovaquone, USP.

The atovaquone particles, reduced in size to facilitate absorption, are significantly smaller than those in the previously marketed tablet formulation. Atovaquone oral suspension, USP is for oral administration and is bright yellow with a citrus flavor. Each teaspoonful (5 mL) contains 750 mg of atovaquone, USP and the inactive ingredients benzyl alcohol, flavor (ethanol, propylene glycol, triacetin), poloxamer 188, purified water, saccharin sodium and xanthan gum.

How it works: Atovaquone is a quinone antimicrobial drug . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 54423fee-da60-25dc-e063-6294a90a2552. Read the full official label on DailyMed.

Related medicines

Amoxicillin Azithromycin Doxycycline Amoxicillin and Clavulanate Cephalexin Valacyclovir Sulfamethoxazole and Trimethoprim Nitrofurantoin